Homeopathic Spray for Snoring Recalled Due to Microbial Contamination
SnoreStop NasoSpray is a nasal spray used to temporarily help stop or reduce symptoms of nonapneic snoring.
Respiratory Diseases/Disorders
Nasal Therapy Improves Chronic Sinusitis Symptoms, Inflammation
OPN-375 is currently marketed under the brand name Xhance for the treatment of nasal polyps in patients 18 years of age and older.
FDA Authorizes Direct-to-Consumer Test to Detect COVID-19, Influenza, and RSV
The test is the first non-prescription multi-analyte COVID-19 test that allows individuals to test nasal swab samples self-collected at home.
Long-COVID Lung Disease: Researchers Characterize 3 Phenotypes
Can long-COVID lung diseases be better understood and classified via analysis of abnormalities seen on transbronchial lung cryobiopsies?
Efzofitimod Granted Orphan Drug Status for Systemic Sclerosis
In preclinical studies, efzofitimod was found to prevent inflammation and fibrosis in multiple animal models of systemic sclerosis and idiopathic pulmonary fibrosis.
Sabizabulin Cuts COVID-19 Death; Trial Stopped Early Due to Efficacy
The phase 3 trial included approximately 210 patients hospitalized with moderate to severe COVID-19 (WHO ≥4) who were at high risk for ARDS and death.
Tocilizumab Gets Priority Review for Treatment of Hospitalized COVID-19 Patients
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
Age-Related Shifts in Nasopharyngeal Microbiome May Affect COVID-19 Susceptibility
Researchers conducted a study to determine whether age-related changes in microbiome composition are associated with an increased susceptibility and risk for COVID-19 infection.
FDA Tells Philips Respironics to Increase Awareness of Product Recall
The Agency issued the notification order as it deemed the Company’s notification efforts to be inadequate.
Drug-Device Combo Looks Promising for Chronic Sinusitis
OPN-375 is currently marketed under the brand name Xhance for the treatment of nasal polyps in patients 18 years of age and older.
- Loading...
Loading...
Next post in News
Loading... 
Loading...